What did Leerink say in the March 16, 2026 note on SYRE analyst rating?

Leerink reiterated an Outperform on Spyre, citing strong clinical execution. The note did not set a new SYRE price target but supported continued upside based on upcoming trial milestones.

Did the March 16 rating change move the SYRE stock price?

Yes. The maintained Outperform coincided with a **0.94%** intraday rise, equal to **$0.41**. The move reflects modest positive investor reaction to the note.

Are there other analyst firms changing a SYRE rating recently?

No. The March 16 note from Leerink Partners is the only recent analyst action recorded. Historical coverage has been concentrated with Leerink and conference presentations.

How should investors use this SYRE analyst rating?

Treat the maintained Outperform as a supportive signal for clinical progress, not as a buy recommendation. Monitor trial data, cash runway, and any future SYRE price target updates before changing allocations.

Analyst Ratings

Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026

ByHuzaifa Zahoor March 17, 2026March 17, 2026

Leerink Partners maintained an Outperform on Spyre Therapeutics, Inc. (SYRE) on March 16, 2026 after citing strong clinical execution. This SYRE analyst rating confirms Leerink’s positive view following Spyre’s recent presentation at the Leerink Global Healthcare Conference. The note showed no new price target, but the rating coincided with a 0.94% intraday rise, or $0.41, in SYRE shares.